| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kirstin J Lauritsen, Harold Rosenber. Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana. The American journal of drug and alcohol abuse. vol 42. issue 4. 2017-11-06. PMID:26910181. |
comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana. |
2017-11-06 |
2023-08-13 |
Not clear |
| Carla Contreras Narváez, Montserrat Mola Gilbert, Enric Batlle de Santiago, Jordi Bigas Farreres, Eloy Giné Serven, Josep Cañete Crespill. Cannabinoid hyperemesis syndrome. A report of six new cases and a summary of previous reports. Adicciones. vol 28. issue 2. 2017-11-06. PMID:26990261. |
cannabinoid hyperemesis syndrome (chs) is a medical condition which was identified for the first time in 2004 and affects chronic users of cannabis. |
2017-11-06 |
2023-08-13 |
Not clear |
| Kristin E Maple, Kymberly A McDaniel, Skyler G Shollenbarger, Krista M Lisdah. Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study. The American journal of drug and alcohol abuse. vol 42. issue 4. 2017-11-06. PMID:27074158. |
findings from animal studies indicate that higher endocannabinoid levels promote sleep, suggesting that chronic use of cannabis, which downregulates endocannabinoid activity, may disrupt sleep. |
2017-11-06 |
2023-08-13 |
Not clear |
| Thangavelu Soundara Rajan, Domenico Scionti, Francesca Diomede, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Lucio Cocco, Placido Bramanti, Emanuela Mazzon, Oriana Trubian. Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. Journal of cellular biochemistry. vol 118. issue 4. 2017-11-03. PMID:27714895. |
cannabidiol, a non-psychotrophic cannabinoid, has been demonstrated as a potent anti-inflammatory and neuroprotective agent in neurological preclinical models. |
2017-11-03 |
2023-08-13 |
human |
| Fernando Correa, Manuel L Wolfson, Paula Valchi, Julieta Aisemberg, Ana María Franch. Endocannabinoid system and pregnancy. Reproduction (Cambridge, England). vol 152. issue 6. 2017-10-31. PMID:27798285. |
therefore, alterations in this system, either by recreation/therapeutic use of cannabis or deregulation of the endogenous cannabinoids, might lead to adverse pregnancy outcomes, including retardation in embryo development, poor blastocyst implantation, inhibition of decidualization, miscarriage and compromised placentation. |
2017-10-31 |
2023-08-13 |
human |
| Matthew Goldenberg, Mark William Reid, Waguih William IsHak, Itai Danovitc. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug and alcohol dependence. vol 174. 2017-10-31. PMID:28319753. |
the impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis. |
2017-10-31 |
2023-08-13 |
Not clear |
| Matthew Goldenberg, Mark William Reid, Waguih William IsHak, Itai Danovitc. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug and alcohol dependence. vol 174. 2017-10-31. PMID:28319753. |
the use of cannabis or cannabinoids to treat medical conditions and/or alleviate symptoms is increasingly common. |
2017-10-31 |
2023-08-13 |
Not clear |
| Hassan Abbassian, Benjamin J Whalley, Vahid Sheibani, Mohammad Shaban. Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. British journal of pharmacology. vol 173. issue 22. 2017-10-30. PMID:27545646. |
cannabinoid (cb) receptor agonists can cause motor disturbances; although, there are also anecdotal reports of therapeutic benefits of cannabis in motor disorders. |
2017-10-30 |
2023-08-13 |
rat |
| Mason M Silveira, Jonathon C Arnold, Steven R Laviolette, Cecilia J Hillard, Marta Celorrio, María S Aymerich, Wendy K Adam. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neuroscience and biobehavioral reviews. vol 76. issue Pt B. 2017-10-30. PMID:27639448. |
this review describes new work examining the behavioural and neural effects of cannabis and the endocannabinoid system, highlighting key regions within corticolimbic brain circuits. |
2017-10-30 |
2023-08-13 |
human |
| Mason M Silveira, Jonathon C Arnold, Steven R Laviolette, Cecilia J Hillard, Marta Celorrio, María S Aymerich, Wendy K Adam. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neuroscience and biobehavioral reviews. vol 76. issue Pt B. 2017-10-30. PMID:27639448. |
first, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as thc, and review studies demonstrating that thc-induced impairments in decision-making processes are mediated by actions at prefrontal cb |
2017-10-30 |
2023-08-13 |
human |
| Jerod Rasmussen, B J Casey, Theo G M van Erp, Leanne Tamm, Jeffery N Epstein, Claudia Buss, James M Bjork, Brooke S G Molina, Katerina Velanova, Daniel H Mathalon, Leah Somerville, James M Swanson, Tim Wigal, L Eugene Arnold, Steven G Potki. ADHD and cannabis use in young adults examined using fMRI of a Go/NoGo task. Brain imaging and behavior. vol 10. issue 3. 2017-10-16. PMID:26489976. |
cannabis use was associated with hippocampal and cerebellar activation, areas rich in cannabinoid receptors, in lncg but not adhd participants. |
2017-10-16 |
2023-08-13 |
human |
| Lance R McMaho. Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys. Drug and alcohol dependence. vol 165. 2017-10-09. PMID:27289270. |
cannabidiol, a therapeutic with potential serotonin (5-hydroxytryptamine; 5-ht) 5-ht1a receptor agonist activity, is the second most prevalent cannabinoid in cannabis after Δ(9)-thc. |
2017-10-09 |
2023-08-13 |
monkey |
| Jaderson V Ferreira, Gisele A Chaves, Bianca L B Marino, Kessia P A Sousa, Lucilene R Souza, Maiara F B Brito, Hueldem R C Teixeira, Carlos H T P da Silva, Cleydson B R Santos, Lorane I S Hage-Meli. Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa. ChemMedChem. vol 12. issue 16. 2017-10-09. PMID:28417566. |
cannabinoid type 1 receptor (cb1) ligands with therapeutic potential for withdrawal syndrome in chemical dependents of cannabis sativa. |
2017-10-09 |
2023-08-13 |
human |
| Mellar P Davi. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network : JNCCN. vol 14. issue 7. 2017-10-04. PMID:27407130. |
multiple studies, most of which are of moderate to low quality, demonstrate that tetrahydrocannabinol (thc) and oromucosal cannabinoid combinations of thc and cannabidiol (cbd) modestly reduce cancer pain. |
2017-10-04 |
2023-08-13 |
Not clear |
| Mellar P Davi. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network : JNCCN. vol 14. issue 7. 2017-10-04. PMID:27407130. |
there are few randomized smoked or vaporized cannabis trials in cancer on which to judge the benefits of these forms of cannabinoids on symptoms and the clinical course of cancer. |
2017-10-04 |
2023-08-13 |
Not clear |
| Kevin M Gutierrez, Theodore V Coope. The use of social networking sites: A risk factor for using alcohol, marijuana, and synthetic cannabinoids? Drug and alcohol dependence. vol 163. 2017-10-03. PMID:27106114. |
the use of social networking sites: a risk factor for using alcohol, marijuana, and synthetic cannabinoids? |
2017-10-03 |
2023-08-13 |
Not clear |
| Kevin M Gutierrez, Theodore V Coope. The use of social networking sites: A risk factor for using alcohol, marijuana, and synthetic cannabinoids? Drug and alcohol dependence. vol 163. 2017-10-03. PMID:27106114. |
the present study builds on past research by examining the relationship between alcohol, marijuana, and synthetic cannabinoid use (e.g., spice, k2) and time spent on sns in a sample of college students. |
2017-10-03 |
2023-08-13 |
Not clear |
| Young Sun Hwang, Youn-Jung Kim, Mi Ok Kim, Mingyeong Kang, Sae Woong Oh, Youn Hwa Nho, See-Hyoung Park, Jongsung Le. Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chemico-biological interactions. vol 273. 2017-10-02. PMID:28601556. |
in addition, the melanogenic effect of cannabidiol was found to be mediated by cannabinoid cb |
2017-10-02 |
2023-08-13 |
human |
| Ewa Kozela, Ana Juknat, Fuying Gao, Nathali Kaushansky, Giovanni Coppola, Zvi Voge. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. Journal of neuroinflammation. vol 13. issue 1. 2017-09-29. PMID:27256343. |
pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune t cells. |
2017-09-29 |
2023-08-13 |
mouse |
| Ewa Kozela, Ana Juknat, Fuying Gao, Nathali Kaushansky, Giovanni Coppola, Zvi Voge. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. Journal of neuroinflammation. vol 13. issue 1. 2017-09-29. PMID:27256343. |
our previous studies showed that the non-psychoactive cannabinoid, cannabidiol (cbd), ameliorates the clinical symptoms in mouse myelin oligodendrocyte glycoprotein (mog)35-55-induced experimental autoimmune encephalomyelitis model of multiple sclerosis (ms) as well as decreases the memory mog35-55-specific t cell (tmog) proliferation and cytokine secretion including il-17, a key autoimmune factor. |
2017-09-29 |
2023-08-13 |
mouse |